Corneal Verticillata After Dual Anti-Epidermal Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Therapy (Vandetanib) for Anaplastic Astrocytoma

Yeh, Steven; Fine, Howard A.; Smith, Janine A.

doi:10.1097/ico.0b013e3181922146

Cited by 23 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been only two reports of vortex keratopathy arising after EGFR inhibitor use, namely vandetanib and suramin, an antiparasitic medication that inhibits EGF, platelet-derived growth factor, and tumor growth factor-beta activity [18,19]. Discontinuation of suramin resulted in clearing of the cornea despite persistent corneal opacification and improvement in the patient's ophthalmic symptoms was observed after vandetanib dose reduction.…”

Section: Discussionmentioning

confidence: 99%

“…Discontinuation of suramin resulted in clearing of the cornea despite persistent corneal opacification and improvement in the patient's ophthalmic symptoms was observed after vandetanib dose reduction. Interestingly, the patient using vandetanib had underlying epithelial basement membrane dystrophy and a history of recurrent corneal erosions, which may have predisposed her to the development of abnormalities in corneal epithelial wound healing [18]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer

Ahn

Wee

Lee

et al. 2011

Korean J Ophthalmol

View full text Add to dashboard Cite

We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer

Ahn

Wee

Lee

et al. 2011

Korean J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…It is used for the treatment of non-small cell lung cancer. There are several reports of the development of a cornea verticillata during vandetanib therapy 40,41. A cornea verticillata appears as vortex-like brownish lines within the corneal epithelium.…”

Section: Vandetanibmentioning

confidence: 99%

Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Häger

Seitz

2013

OTT

View full text Add to dashboard Cite

During the last 20 years, biologicals have become increasingly relevant in oncologic therapy. Depending on the medication used, there are different profiles of ocular side effects. Although these can be present in up to 70% of patients, they are generally underreported in the literature. Therefore, the pathophysiological details of their development are often poorly understood. Herein we attempt to identify groups of biologicals to which a specific side effect profile can be assigned. We also tried to capture all relevant side effects and therefore conducted several database investigation including Medline, Cochrane library, and the drugs section of the US Food and Drug Administration (FDA), using the following search strings: “name of biological agent (both generic and commercial names)” AND “eye” OR “ocular”. If we found a side effect that has been associated with a drug, we researched Medline using the following search string: “name of biological agent” (both generic and commercial names) AND “term for the specific side effect”. Due to the wealth of material we report only the drugs that are approved by the FDA.

show abstract

“…Also, tortuous eyelashes associated with gefitinib, corneal opacities with administration of high doses of EGFR inhibitors, trichomegaly and periorbital rash after erlotinib administration are reported [12–14]. Similarly, symptomatic corneal verticillata was observed after vandetanib therapy for anaplastic astrocytoma [15]. …”

Section: Corneal Manifestationsmentioning

confidence: 99%

Ocular toxicity from systemically administered xenobiotics

Gokulgandhi

Vadlapudi

Mitra

2012

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

Introduction The eye is considered as the most privileged organ because of the blood–ocular barrier that acts as a barrier to systemically administered xenobiotics. However, there has been a significant increase in the number of reports on systemic drug-induced ocular complications. If such complications are left untreated, then it may cause permanent damage to vision. Hence, knowledge of most recent updates on ever-increasing reports of such toxicities has become imperative to develop better therapy while minimizing toxicities. Areas covered The article is mainly divided into anterior and posterior segment manifestations caused by systemically administered drugs. The anterior segment is further elaborated on corneal complications where as the posterior segment is focused on optic nerve, retinal and vitreous complications. Furthermore, this article includes recent updates on acute and chronic ocular predicaments, in addition to discussing various associated symptoms caused by drugs. Expert opinion Direct correlation of ocular toxicities due to systemic drug therapy is evident from current literature. Therefore, it is necessary to have detailed documentation of these complications to improve understanding and predict toxicities. We made an attempt to ensure that the reader is aware of the characteristic ocular complications, the potential for irreversible drug toxicity and indications for cessation.

show abstract

Corneal Verticillata After Dual Anti-Epidermal Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Therapy (Vandetanib) for Anaplastic Astrocytoma

Cited by 23 publications

References 24 publications

Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer

Vortex Keratopathy in a Patient Receiving Vandetanib for Non-Small Cell Lung Cancer

Ocular side effects of biological agents in oncology: what should the clinician be aware of?

Ocular toxicity from systemically administered xenobiotics

Contact Info

Product

Resources

About